MP 101 - Metys Pharmaceuticals
Alternative Names: MP-101 - Metys PharmaceuticalsLatest Information Update: 07 Feb 2023
At a glance
- Originator Neurotune
- Developer Metys Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Glutamate modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuropathic pain